In response to the bipartisan Senate 340B “Gang of Six” working group’s introduction of the SUSTAIN 340B Act on August 5, 2026, Advocates for Community Health (ACH) issued the following statement: “ACH is grateful to Sens. Baldwin (D-WI), Boozman (R-AR), Capito (R-WV), Hickenlooper (D-CO), Kaine (D-VA), and Moran (R-KS) for their leadership to craft comprehensive […]
On July 31, the Health Resources and Services Administration (HRSA) unveiled a new 340B rebate model pilot, triggering immediate reactions across the healthcare sector regarding its potential impact on safety-net providers. The new model which begins January 1, 2027, would change the long-standing program that offers upfront discounts with a new, post-purchase rebate system. While […]
Bloomberg Government reported today that the U.S. Department of Health and Human Services will implement a revised 340B rebate pilot beginning Jan. 1, 2027. The model will require health centers and other covered entities to pay full price for certain drugs and later seek rebates, raising serious concerns about cash-flow disruptions, administrative burdens and the […]
New financial and administrative burdens could force community health centers to reduce services in rural and underserved communities. WASHINGTON — In response to today’s announcement by the U.S. Department of Health and Human Services of a new rebate model for the 340B Drug Pricing Program set to begin on January 1, 2027, Advocates for Community […]
ACH congressional briefing highlighted how 340B savings sustain essential care in rural and underserved communities WASHINGTON — Community health center leaders urged Congress to protect and strengthen the 340B Drug Pricing Program during a congressional briefing hosted Wednesday on Capitol Hill by Advocates for Community Health (ACH), a leading nonpartisan, nonprofit membership organization representing some […]
A new Roll Call article examines the intensifying debate over the future of the 340B Drug Pricing Program as lawmakers consider competing proposals and pharmaceutical manufacturers impose new restriction. ACH CEO Amanda Pears Kelly was interviewed for this story. The article highlights several major developments, including bipartisan legislation from Reps. Scott Peters (D-Calif.) and John […]
Health center leaders will discuss how 340B savings expand access to affordable medications and essential patient services—and how proposed changes could threaten care. WASHINGTON — Advocates for Community Health (ACH), a national nonpartisan, nonprofit organization representing community health centers, will host a congressional briefing, “The 340B Program: A Lifeline for Community Health Centers,” on Wednesday, […]
The 340B Drug Pricing Program is a game changer for federally qualified health centers (FQHCs), which have limited flexible funding streams at their disposal and often use their 340B savings for services that are non-reimbursable. The financial impact of these savings cannot be overstated, as they allow FQHCs to stretch their already scarce federal resources […]
The 340B Drug Pricing Program is entering one of its most consequential periods in years. Congress is actively considering multiple reform proposals, HRSA is moving forward with a proposed rebate model, pharmaceutical manufacturers continue expanding claims data requirements, and litigation over contract pharmacies remains ongoing. Against this rapidly changing backdrop, Advocates for Community Health (ACH) […]
Data has become one of the most powerful tools in healthcare, helping demonstrate impact, improve quality, and inform key policy decisions. For community health centers, the Uniform Data System (UDS) serves as the nation’s annual snapshot of the Health Center Program, which captures key information on the patients served, services provided, workforce, and health outcomes. […]
